. 2010 Sep 21;60(1):23–35. doi: 10.1007/s00262-010-0916-z

Table 1.

Patient characteristics and tumor antigen expression

Patients	Age^a	Gender	Tumor localization	Stage	MAGE expression^b
Patients	Age^a	Gender	Tumor localization	Stage	A3	A4
LAU 2032	72	M	Oral cavity	IV	+	+++
LAU 2042	69	F	Oral cavity	III	++	+++
LAU 2068	68	F	Oral cavity	IV	+++	+++
LAU 2069	64	F	Oropharynx	III	+++	++
LAU 2073	54	M	Oropharynx	IV	+++	++
LAU 2086	68	M	Larynx	III	−	+++
LAU 2091	68	M	Oropharynx	II	−	++

−, negative; +, 1–5%; ++, 5–50%; +++, >50% level of expression

^aCalculated at the surgery date

^bEvaluated by RT–PCR (quantitative assessment was performed as previously described, using 1:10 dilutions of SK-Mel-37 RNA as reference [38])